MRUS Company Profile and Key Details
Merus N.V.
MRUS Stock Price Chart
Stock Price Today
Merus N.V. (MRUS) stock surged +2.24%, trading at $40.63 on NASDAQ, up from the previous close of $39.74. The stock opened at $39.40, fluctuating between $39.28 and $40.98 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Company Information
| Employees | 172 |
| Beta | 1.12 |
| Sales or Revenue | $43.95M |
| 5Y Sales Change% | -0.472% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Merus N.V. (NASDAQ: MRUS) stock price is $40.63 in the last trading session. During the trading session, MRUS stock reached the peak price of $40.98 while $39.28 was the lowest point it dropped to. The percentage change in MRUS stock occurred in the recent session was 2.24% while the dollar amount for the price change in MRUS stock was $0.89.
The NASDAQ listed MRUS is part of Biotechnology industry that operates in the broader Healthcare sector. Merus N.V. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Gregory D. Perry
Chief Financial Officer & Vice Chairman
Dr. Sven Ante Lundberg M.D.
Chief Executive Officer, Pres & Executive Director
Mr. Peter B. Silverman J.D.
EVice President, Company Sec., Chief Operating Officer, Gen. Counsel, Chief Intellectual Property Officer & Head of US Legal
Dr. Cecilia Anna Wilhelmina Geuijen Ph.D.
Chief Scientific Officer & Senior Vice President
Mr. Hui Liu Ph.D.
Chief Bus. Officer, Executive Vice President & Head of Merus U.S.
Harry Shuman
Chief Accounting Officer
Dr. Hennie Hoogenboom
Co-Founder and Scientific Advisor
Mr. Alexander Berthold Hendrik Bakker Ph.D.
Chief Devel. Officer & Executive Vice President
Mr. Cornelis Adriaan de Kruif Ph.D.
Chief Technology Officer & Executive Vice President
Ms. Jillian Connell
Vice President of Investor Relations & Corporation Communications
Dr. Andrew Joe M.D.
Chief Medical Officer & Senior Vice President
Dr. Hui Liu Ph.D.
Chief Bus. Officer, Executive Vice President & Head of Merus U.S.
MRUS's closing price is 20.92% higher than its 52-week low of $33.60 where as its distance from 52-week high of $61.61 is -34.05%.
Number of MRUS employees currently stands at 172.
Official Website of MRUS is: https://www.merus.nl
MRUS could be contacted at phone 313 025 38800 and can also be accessed through its website. MRUS operates from Yalelaan 62, Utrecht, 3584 CM, Netherlands.
MRUS stock volume for the day was 379.08K shares. The average number of MRUS shares traded daily for last 3 months was 590.61K.
The market value of MRUS currently stands at $2.78B with its latest stock price at $40.63 and 68.46M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com